Cite
HARVARD Citation
Sengupta, N. et al. (2020). Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian journal of gastroenterology. pp. 800-805. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sengupta, N. et al. (2020). Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian journal of gastroenterology. pp. 800-805. [Online].